#### AMENDMENT

U.S. Appln. No. 09/599,002

### IN THE SPECIFICATION:

The specification is amended as follows:

Page 9, lines 14-28, are amended as follows:

## FcγRIIA

EC2-131R : 5'CCAGAATGGAAAATCCCAGAAATTCTCTCG3' (SEQ ID NO:1)

EC2-131H : 5'CCAGAATGGAAAATCCCAGAAATTCTCTCA3' (SEQ ID NO:2)

TM1 : 5'CCATTGGTGAAGAGCTGCCCATGCTGGGCA3'\_(SEQ ID NO:3)

Control 1 : 5'GATTCAGTGACCCAGATGGAAGGG3' (SEQ ID NO:4)

Control 2 : 5'AGCACAGAAGTACACCGCTGAGTC3' (SEQ ID NO:5)

# FcγRIIA

NA1 : 5'CAGTGGTTTCACAATGTGAA3' (SEQ ID NO:6)

NA2 : 5'CAATGGTACAGCGTGCTT3' (SEQ ID NO:7)

Reverse primer: 5'ATGGACTTCTAGCTGCAC3' (SEQ ID NO:8)

Control 1 : 5'CAGTGCTTCCCAACCATTCCCTTA3' (SEQ ID NO:9)

Control 2 : 5'ATCCACTCACGGATTTCTGTTGTGTTTC3' (SEQ ID

NO:10)

Page 11, between lines 1-5 are amended as follows: drawings in which:

# BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a plot of the probability of multiple sclerosis patients being able to walk without support (crutches or cane) correlated to duration of disease and FcyRIIIB genotype; and